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ORIGINAL ARTICLE
Background/Aims: Fabry disease is an X-linked recessive and progressive disease caused by α-galactosidase A
(α-GaL A) deficiency. We sought to assess the prevalence of unrecognized Fabry disease in dialysis-dependent
patients and the efficacy of serum globotriaosylceramide (GL3) screening. 
Methods: A total of 480 patients of 1,230 patients among 17 clinics were enrolled. Serum GL3 levels were
measured by tandem mass spectrometry. Additionally, we studied the association between increased GL3 levels
and cardiovascular disease, cerebrovascular disease, or left ventricular hypertrophy. 
Results: Twenty-nine patients had elevated serum GL3 levels. The α-GaL A activity was determined for the 26
patients with high GL3 levels. The mean α-GaL A activity was 64.6 nmol/hr/mg (reference range, 45 to 85), and no
patient was identified with decreased α-GaL A activity. Among the group with high GL3 levels, 15 women had a α-
GaL A genetics analysis. No point mutations were discovered among the women with high GL3 levels. No
correlation was observed between serum GL3 levels and α-GaL A activity; the Pearson correlation coefficient was
0.01352 (p = 0.9478). No significant correlation was observed between increased GL3 levels and the frequency of
cardiovascular disease or cerebrovascular disease. 
Conclusions: Fabry disease is very rare disease in patients with end-stage renal disease. Serum GL3
measurements as a screening method for Fabry disease showed a high false-positive rate. Thus, serum GL3
levels determined by tandem mass spectrometry may not be useful as a screening method for Fabry disease in
patients with end stage renal disease. (Korean J Intern Med 2010;25:415-421)
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INTRODUCTION
Fabry disease is an X-linked recessive and progressive
multiorgan lysosomal storage disease caused by α-galact-
osidase A (α-GaL A) deficiency. Because the disease is X-
linked, males (hemizygotes) are predominantly affected,and females (heterozygotes) are obligate carriers. The
partial or complete deficiency of the lysosomal enzyme
leads to an accumulation of neutral glycosphingolipids,
especially globotriaosylceramide (GL3), in the vascular
endothelium and visceral tissues throughout the body.
This lipid accumulation leads to significant morbidity,
especially in affected males. Many female carriers can also
be affected, but because of random X-inactivation, they
usually present with a more variable phenotype [1].
Therefore, females usually manifest the disease at a later
age, although a homozygous female has been described
with severe onset of classical disease at 8 years of age [2].
The prevalence of Fabry disease has been estimated to
be 1 in 40,000 to 117,000 males, and the prevalence may
be higher in patients with end-stage renal disease (ESRD)
[3-8].
Fabry disease presents with a characteristic phenotype
that varies and may include angiokeratoma, corneal
opacity, acroparesthesia, cerebrovascular disease,
ischemic heart disease, and chronic kidney disease.
However, in addition to the classical Fabry disease
phenotype, variants of Fabry disease exist. For example,
the cardiac and renal variants show manifestations
limited to the heart and kidneys, respectively. The renal
variant of Fabry disease is characterized by proteinuria
and chronic renal insufficiency in the absence of other
clinical symptoms associated with classical Fabry disease.
The cardiac variant of Fabry disease has primarily cardiac
manifestations, including left ventricular hypertrophy
(LVH), valvular involvement, and arrhythmias, but no
other classical symptoms of Fabry disease. This variant
was first noted in pathological studies of endomyocardial
biopsy specimens and autopsy specimens of the heart [9].
For patients with the renal variant type, the renal
manifestations generally occur later in life, and a greater
residual α-GaL A activity is found in these patients [10]. 
Recently, enzyme replacement therapy for Fabry
disease has shown that renal pathology and function can
be improved with treatment. Therefore, early detection of
renal involvement of Fabry disease is important for the
prevention of progression to ESRD. Furthermore, patients
with ESRD can be protected from cardiovascular and
cerebrovascular complications by treatment with enzyme
replacement therapy [11-13]. Therefore, an accurate and
affordable screening method is needed to diagnose the
disease as early as possible for prompt intervention.
Some screening methods for Fabry disease are available
that determine the α-GaL A activity from a variety of
sources. However, the α-GaL A activity method is not
widely available for screening. Therefore, the goal of this
study was to assess the prevalence of unrecognized Fabry
disease in patients with ESRD on maintenance dialysis
by measuring serum GL3 levels by tandem mass
spectrometry, and the efficacy of serum GL3 as a
screening method for Fabry disease was evaluated.
METHODS
Patients
Seventeen hemodialysis clinics in the Seoul and
Gyeonggi-do regions of Korea participated in the Fabry
disease screening program during 2005. From among
patients receiving maintenance dialysis for more than 3
months, each of the clinics randomly selected male
patients more than 40 years of age and female patients
more than 50 years of age. The enrolled patients had no
specific diagnosis for their ESRD. 
Patient characteristics
We collected information on the characteristics of the
screened participants including duration of renal disease,
duration of dialysis, history of cardiovascular (myocardial
infarction and angina pectoris) and cerebrovascular
disease (stroke), and the presence of LVH on electrocar-
diogram (ECG).
Screening test by serum globotriaosylceramide
(GL3) measurement
Blood samples were collected before dialysis, and the
serum was separated. The GL3 levels were measured by
tandem mass spectrometry using an API4000 instrument
(MDS Sciex, Ontario, Canada). The serum GL3 level
reference range in a normal person is 3.88 to 9.87 µg/mL.
We defined patients with a serum GL3 level in the
reference range as the “normal GL3 group” and patients
with serum GL3 levels above the reference range as the
“high GL3 group.”
Confirmation test by α α-GaL A activity measure-ment
For the patients in the high GL3 group, we measured
the α-GaL A activity on peripheral blood leukocytes by a
fluorescence assay with 4-methylumbelliferyl. The
reference range of α-GaL A activity in normal persons is
45 to 85 nmol/hr/mg in leukocytes.
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We confirmed the presence of Fabry disease by analy-
zing patients for the α-GaL A mutation using PCR-
sequence analysis. Additionally, we assessed the clinical
manifestations of patients with significantly decreased α-
GaL A activity, as well as female patients with high GL3
levels. Genomic DNA was isolated from peripheral blood
leukocytes using the PUREGENE blood kit (Genta,
Minneapolis, MN, USA).
Mutation analysis was performed by polymerase chain
reaction (PCR) to amplify each of the seven α-GaL A exon
and intron sequences. The amplification was performed
over 30 cycles; each cycle consisted of denaturing at 95˚C
for 30 seconds, annealing at 55˚C  for 30 seconds, and
extension at 72˚Cfor 45 seconds. The PCR was conducted
in reaction volumes of 20 µL, containing 100 ng of
genomic DNA template, 1 µM of each primer, 200 µM
each of dNTP, 1.5 mM MgCl2, 50 mM KCl, and 10 mM
Tris-HCl (pH 8.3), and 1.0 unit of Taq polymerase
(Promega, Madison, WI, USA). The PCR was performed
in a PTC-200 thermocycler (MJ Research, Watertown,
MA, USA). Double-stranded DNA was directly sequenced
from the PCR products using the same primers as the
PCR with the BigDye Termination version 3.0 (ABI
Systems, Forester, CA, USA). 
The sequences were diluted in eight volumes of enzyme
dilution buffer (400 mM Tris-HCl; 10 mM MgCl2; pH
9.0). After the reaction was finished, the reactants were
electrophoresed on an ABI3100 Genetic Analyzer (ABI
Systems), with the POP-6 polymer as the running matrix.
The sequences were analyzed with ABI PRISM Sequence
Analysis version 3.7 (ABI Systems).
Statistical analysis
Qualitative variables were compared by the chi-square
test, and the Pearson correlation analysis was also used.
Analyses were performed using SPSS version 11.0 (SPSS
Inc., Chicago, IL, USA).
RESULTS
Measurement of serum GL3
Four-hundred eighty patients (311 men and 169
women) were selected from 1,230 patients (670 men and
560 women) among the 17 hemodialysis clinics. Patients
with clinically identified causes of ESRD were excluded
from the study, such as patients with polycystic kidney
disease, biopsy-proven disease, and diabetic nephropathy.
The serum GL3 levels ranged from 0.96 µg/mL to 15.85
µg/mL. The mean serum GL3 level was 6.45 ± 2.28
µg/mL (males, 6.14 ± 2.16 µg/mL; females, 7.00 ± 2.37
µg/mL) (Fig. 1).
Characteristics of the patients with a high GL3 
Among the 480 selected patients, 29 patients (6.0%)
had high serum GL3 levels. Twelve patients (2.5%) were
male and 17 patients (3.5%) were female. The mean age
was 63.4 ± 13.1 years in the high GL3 group and 53.1 ± 13
years in the normal GL3 group (p < 0.05). Dividing the
high GL3 group by sex revealed that the mean age was
64.0 ± 11.3 years in men and 63.1 ± 14.5 years in women.
The mean duration of renal disease was 93.2 ± 51.5
months in the high GL3 group and 109.8 ± 80.8 months
in the normal GL3 group (p = 0.045). The mean duration
of dialysis was 57.1 ± 40.8 months in the high GL3 group
and 89.7 ± 74.1 months in the normal GL3 group (p =
0.046).
We investigated the relationship between increased GL3
levels and cardiovascular disease, cerebrovascular disease,
and LVH. A significant increase in the frequency of LVH
in the high GL3 group was observed. The prevalence of
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Figure 1. Frequency of globotriasoylceramide (GL3) levels.
Patients with serum GL3 levels in the reference range as the
‘normal GL3 group’ and patients with serum GL3 levels above
the reference range as the ‘high GL3 group’ (reference range of
serum GL3, 3.88 to 9.87 µg/mL). Serum GL3 levels ranged
0.96 to 15.85 µg/mL. The mean serum GL3 level was 6.45 ±
2.28 µg/mL.LVH in patients in the high GL3 group was 77.8%,
whereas patients without LVH accounted for 22.2% (p =
0.002). Therefore, a significant increase in the frequency
of LVH was observed in the high GL3 group. However, no
significant increase in the frequency of cardiovascular or
cerebrovascular disease was observed (Table 1).
Interview of patients in the high GL3 group  
Among 29 patients in the high GL3 group, one patient
died (GL3 = 15.85 µg/mL) and two patients were lost to
follow-up (GL3 = 11.13 and 10.34 µg/mL). Thus, we
interviewed 26 patients with high GL3 levels. We asked
about family history of renal disease of unknown cause
and about symptoms and signs related to Fabry disease,
such as angiokeratoma and acroparesthesia. However, no
patients identified a family history suggesting Fabry
disease.
Measurement of α α-GaL A activity
The mean α-GaL A activity of the 26 patients with high
GL3 levels was 64.6 nmol/hr/mg (range, 34.6 to 165.1 ).
No patients were found in whom α-GaL A activity had
decreased significantly, and, therefore, no cases of Fabry
disease were identified. The correlation between serum
GL3 levels and α-GaL A is shown in Fig. 2. The Pearson's
correlation coefficient between the serum GL3 and α-GaL
A activity was 0.01352 (p= 0.9478).
Molecular analysis of the α α-GaL A gene
Among 26 patients (9 males and 17 females) with high
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Table 1. The relationship between serum GL3 levels and cardiovascular disease, cerebrovascular disease, and LVH
GL3 p value
Normal High
LVH + 149 (40.8) 14 (77.8) 0.002
- 217 (59.2) 4 (22.2)
Cardiovascular disease + 31 (9.1) 4 (19.1) 0.098
- 351 (90.9) 17 (80.9)
Cerebrovascular disease + 26 (6.9) 3 (14.3) 0.149
- 356 (93.1) 18 (85.7)
Values are presented as number (%).
GL3, globotriaosylceramide; LVH, left ventricular hypertrophy.
Figure 2. Correlation between the serum globotriasoyl ceramide
(GL3) and α-galactosidase A activity. The pearson correlation
coefficient between the serum GL3 and α-galactosidase A
activity was 0.01352 (p = 0.9478). There was no correlation
between the serum GL3 levels and the α-galactosidase A
activity.
Figure 3. Flow chart illustrating the study. Among 1,230 patients,
there was no Fabry patient detected. GL3, globotriaosylceramide.GL3 levels, 15 women (two lost to follow-up) were
evaluated by restriction analysis to confirm whether a
point mutation of the α-GLA gene was present. The
genetic analysis showed no point mutations among the
women with high GL3 levels (Fig. 3).
DISCUSSION
The current Fabry disease model describes the
accumulation of GL3 in different organs leading to severe
organ damage [14]. Therefore, effective screening
methods are needed for the early detection of Fabry
disease before it causes irreversible harm.
Several screening methods for Fabry disease have been
introduced. One method is detecting α-GaL A activity. α-
GaL A activity screening can be performed on a variety of
biological materials including leukocytes, dried whole
blood spots, serum, and plasma. The limitation of this
method is that abnormal values must be confirmed by a
more reliable source such as blood leukocytes, and
measurement of α-GaL A activity cannot detect all female
carriers. For female heterozygous patients, a very low level
of α-GaL A is diagnostic of the Fabry carrier state.
However, a normal or subnormal enzyme activity level
does not rule out the possibility that a woman is a carrier
because of random X-chromosome inactivation.
Therefore, all women at risk for carrying the abnormal
gene should have DNA studies [15].
In the newborn, results from dried blood spots and
plasma provide an effective screening method and
concordant results. However, insufficient information is
available to determine whether blood spots are more
reliable than plasma for screening adult patient
populations with renal and/or cardiac disease. It is
reasonable to suspect that the circulating enzyme levels in
adult populations might be influenced by secondary
confounders (dietary, biologic, pathologic, or iatrogenic)
compared with neonates [16].
Another possible method is detecting levels of GL3 in
plasma. Glycosphingolipids (GSLs) are components of
plasma cell membranes, which are synthesized in the
endoplasmic reticulum and Golgi apparatus. A deficiency
of the GSL catalyzing enzymes or cofactors leads to a
specific storage disorder; in the case of Fabry disease, the
enzyme is α-GaL A, and the accumulated substance is
GL3[17,18]. 
In advanced Fabry disease, the levels of GL3 in urine
and plasma and non-neural tissues increase. However,
accurately measuring GL3 in biological samples is difficult
due to the inherent heterogeneity of the GL3 molecule,
which increases the overall complexity of GL3
measurements. Current analytic methods reduce the
complexity of GL3 determinations by measuring “total
GL3,” which is the sum of all GL3 isoforms [19]. The
methods used to measure total GL3 include thin-layer
chromatography, ELISA, liquid chromatography, C-UV,
and gas chromatography-flame ionization. However,
routine use of such methods has been limited by the long
processing time. In contrast, tandem mass spectrometry
requires a relatively short time for analysis, and it can
quantify the isoforms separately.
In this study, 480 patients with ESRD were screened by
assaying serum GL3 using tandem mass spectrometry,
and the α-GaL A activity was determined in the blood
leukocytes of patients with a high GL3. Furthermore,
genetic mutation analysis in female patients with high
GL3 was performed to determine the prevalence of Fabry
disease in an at-risk population of patients with ESRD.
We did not identify any patients with Fabry disease in
these patients on dialysis in our community. We can
explain these results in four ways.
First, the sample size of our study might be too small to
detect Fabry disease considering the relatively low
prevalence of this disease, as reported previously. The
number of male patients on dialysis in our study was 311
among 670 male patients. In previous studies, the number
of male dialysis patients ranged from 440 to 1,516. If we
found only one male with Fabry disease in our study, the
prevalence would have been 0.32%. Therefore, the
number of enrolled male patients should ideally be in
accordance with the prevalence of this disease in a given
region. 
Second, measuring serum GL3 as a screening method
might have been inappropriate. In another study, serum
GL3 levels increased four-fold in patients with classical
Fabry disease compared with normal persons [20].
Among 26 patients who had blood samples drawn for α-
GaL A activity and genetic mutation analysis, we did not
find any cases of Fabry disease, even in those with high
GL3 levels. In our preliminary study, we measured serum
GL3 levels pre-hemodialysis and post-hemodialysis in the
same five patients. The serum GL3 levels in the pre-
hemodialysis compared to post-hemodialysis samples
were not different (data not shown), suggesting that
serum GL3 was not significantly altered by hemodialysis.
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for our study. Serum GL3 was analyzed by tandem mass
spectrometry screening. However, a prior study reported
that serum GL3 levels were not an appropriate screening
method for Fabry disease because the serum GL3 levels
could be within the normal range in heterozygotes with
Fabry disease. Young et al. [21] found that only 33% of
proven heterozygotes (15 of 44) had elevated plasma GL3,
and six male patients (6/6) with the N125S mutation had
normal GL3 levels in plasma. In another study, GL3 levels
were within the normal range in two patients (2/11) [13]
and overlapped between male heterozygotes and a healthy
person [22]. Measuring serum GL3 levels for screening
Fabry disease continues to be debated. We performed a
molecular analysis of the α-GaL A gene in female patients
with high GL3 levels. The patients with high GL3 levels in
this study might have had a cofactor deficiency, or an
unknown enzyme cascade may have existed. Therefore,
further study is needed to identify other relevant
metabolic pathways.
There are other causes for elevated GL3 levels. High
GL3 levels may be associated with many other conditions
such as inflammation, nutritional status, or limited
excretion, or they may be falsely elevated [23]. Therefore,
other factors that influence GL3 levels should be studied. 
Third, a selection bias might have occurred in this
study. The enrolled patients were chosen based on the
attending physician's judgment that there was no specific
diagnosis for the ESRD. Because Fabry disease is a low-
prevalence disease, if only a few patients were missed, the
data would be inaccurate. Fourth, three patients were lost
to follow-up in the high GL3 group. 
Interestingly, the high GL3 group included older
patients, those with a shorter duration of renal disease,
and a shorter duration of dialysis compared with the
normal GL3 group. Additionally, patients with high GL3
levels had a significantly increased prevalence of LVH.
Therefore, further study is needed to explain this
relationship between high GL3 levels and LVH, as well as
high GL3 levels and age. However, the results may be
coincidental.
In summary, we did not identify any patients with Fabry
disease in our cohort with ESRD on maintenance dialysis
using the serum GL3 levels determined by tandem mass
spectrometry. The reason may be that Fabry disease is
very rare, and that the GL3 method showed a high false-
positive rate.
Some patients on maintenance dialysis had increased
serum GL3 levels. However, the reason for the high serum
GL3 levels was not identified, and the elevation of serum
GL3 levels may be due to some other factor than Fabry
disease in patients on maintenance dialysis. The GL3
levels appear not to be useful for screening patients for
Fabry disease who are on maintenance hemodialysis. The
significance of high GL3 levels with advancing age as well
as the progression of ESRD should be further studied. 
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